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Abstract
Background: Lupus nephritis is characterized by deposition of chromatin fragment-IgG complexes in the mesangial matrix
and glomerular basement membranes (GBM). The latter defines end-stage disease.
Methodology/Principals: In the present study we determined the impact of antibodies to dsDNA, renal Dnase1 and matrix
metalloprotease (MMP) mRNA levels and enzyme activities on early and late events in murine lupus nephritis. The major
focus was to analyse if these factors were interrelated, and if changes in their expression explain basic processes accounting
for lupus nephritis.
Findings: Early phases of nephritis were associated with chromatin-IgG complex deposition in the mesangial matrix. A
striking observation was that this event correlated with appearance of anti-dsDNA antibodies and mild or clinically silent
nephritis. These events preceded down-regulation of renal Dnase1. Later, renal Dnase1 mRNA level and enzyme activity
were reduced, while MMP2 mRNA level and enzyme activity increased. Reduced levels of renal Dnase1 were associated in
time with deficient fragmentation of chromatin from dead cells. Large fragments were retained and accumulated in GBM.
Also, since chromatin fragments are prone to stimulate Toll-like receptors in e.g. dendritic cells, this may in fact explain
increased expression of MMPs.
Significance: These scenarios may explain the basis for deposition of chromatin-IgG complexes in glomeruli in early and late
stages of nephritis, loss of glomerular integrity and finally renal failure.
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Introduction
A wide spectrum of autoimmune responses and organ
manifestations are characteristic of Systemic lupus erythematosus
(SLE), and are used by the American College of Rheumatology
(ACR) as criteria to classify SLE. [1] Of particular importance in
context of the present study are criteria linked to development of
kidney disease: Production of potentially pathogenic anti-dsDNA
antibodies (criterion # 10) and deposition of chromatin-containing
immune complexes in kidneys (criterion # 7).
Over time, different concepts have been discussed to describe
possible basic processes linked to initiation of lupus nephritis, and
to progression of mild into end-stage organ disease. There is a
consensus stating that anti-dsDNA and anti-chromatin antibodies
are central in initiation and maintenance of lupus nephritis, but
there is no agreement as to how they interact with glomerular
structures. This could be due to cross-reaction of anti-chromatin
antibodies with inherent glomerular structures like laminin [2–4],
a-actinin [5–7], or with membrane components of mesangial cells
[8,9], or to binding of anti-chromatin antibodies to chromatin
fragments exposed in affected glomeruli. Recent data favour the
latter model.
We have demonstrated that chromatin fragments possess a high
intrinsic affinity for glomerular membrane and matrix components
like laminins and collagen IV [10]. These fragments are observed
as electron dense structures (EDS) along glomerular basement
membranes (GBM) and in the mesangial matrix. Glomerular EDS
are terminal deoxynucleotidyl transferase-mediated dUTP nick
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nicked DNA [10,11]. Furthermore, antibodies to components of
chromatin, like those reactive with DNA, histones or transcription
factors, bind in vitro to antigens present in EDS in murine [12,10]
and human [11] forms of lupus nephritis. Binding of antibodies in
vivo to other structures that are not parts of EDS have not been
observed in these studies [13].
It is not clear why chromatin fragments are exposed in kidneys,
but this phenomenon may be linked to reduced ability of renal
nucleases to degrade apoptotic or necrotic chromatin within the
kidneys. We have recently demonstrated that reduced fragmen-
tation of chromatin during evolution of nephritis concur with an
acquired loss of renal Dnase1 mRNA at the time when nephritis
transforms into end-stage organ disease [14,15]. Dnase1 accounts
for more than 80% of total renal nuclease activity [16]. With low
renal Dnase1 enzyme activity, apoptotic chromatin may not be
appropriately fragmented and may instead be transformed into
secondary necrotic chromatin fragments released from apoptotic
blebs. Secondary to this event, chromatin fragments are exposed
to the environment within kidneys, and bind glomerular
membranes. Chromatin fragments may also be taken up by
macrophages and dendritic cells in which they stimulate TLRs
through CpG (TLR9) or RNA (TLR7) structures [17–23].
Engagement of TLRs may serve two functions: Up-regulation of
co-stimulatory molecules (CD80/CD86) which are important for
activation of chromatin-specific T helper cells [24,25], required to
transform chromatin-specific B cells into anti-chromatin antibody-
secreting plasma cells; and up-regulation of certain matrix
metalloproteases (MMPs) [22,23]. Secreted MMPs have the
potential to disintegrate GBM and the mesangial matrix by
enzymatic degradation [26,27]. This may facilitate deposition of
chromatin fragment-IgG complexes in GBM. In harmony with
this assumption, MMP2 and MMP9 activities are reported to be
increased within glomeruli of nephritic, but not pre-nephritic,
(NZBxNZW)F1 (BW) mice [28].
From data in these referenced studies, we predict that loss of
renal Dnase1 correlates with exposure of large chromatin
fragments within glomeruli and with increased MMP activities
in the kidneys. The present study was designed to analyse how
regulation of Dnase1, MMP2 and MMP9 mRNA levels and
enzyme activities correlate with each other, with production of
antibodies to dsDNA, with successive deposition of EDS in the
mesangial matrix and in GBM, and finally with progressive
proteinuria characteristic of lupus nephritis. The data presented
here may explain the molecular and genetical basis for deposition
of chromatin-IgG complexes in glomeruli in early and late stages
of nephritis, with loss of glomerular integrity and renal failure as
the final outcome.
Results
Dnase1, MMP2 and MMP9 mRNA Levels and
Corresponding Enzyme Activities, and Degree of
Proteinuria in Pre-Nephritic BW Mice and in Mice with
EDS in the Mesangial Matrix or in GBM
BW mice were sacrificed approximately every second week (in
sets of 3) until development of end-stage lupus-like nephritis, and
were analyzed for renal Dnase1, MMP2 and MMP9 mRNA levels
and for corresponding enzyme activities. The mice were initially
divided into 3 groups according to kidney morphology; pre-
nephritic mice (Group 1, no glomerular deposits of EDS (n=27),
Figure 1A), mice with mesangial EDS deposits only (Group 2
(n=17), Figure 1B), or mice with EDS deposits in both mesangial
matrix and in GBM (Group 3 (n=10), Figure 1C). The number of
Figure 1. (NZBxNZW)F1 mice grouped according to glomerular
location of EDS deposits. (NZBxNZW)F1 mice were sacrificed
approximately every second week (in sets of 3) until development of
end-stage lupus-like nephritis. The mice were sorted into 3 main groups
according to kidney morphology; pre-nephritic mice (Group 1, no
glomerular deposits of EDS (n=27), A), mice with mesangial EDS
deposits (Group 2 (n=17), B), or mice with EDS deposits in GBM (Group
3 (n=10), C). Magnification640 k.
doi:10.1371/journal.pone.0008474.g001
Dnase1 in Lupus Nephritis
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8474mice in these groups refers to mice with complete sets of data
(n=54, see Table S1 for complete sets of data in individual mice
identifiable by labels). In analyses of individual parameters, 2
additional mice with relevant data are included. These were not
analyzed for glomerular EDS deposits and are excluded from
Figures 2, 4B, 4C, 5A, 5B and 6. No glomerular deposits of EDS
were observed in sex and age matched BALB/c mice (data not
shown, see also [12]).
As demonstrated in Figure 2A, there were no significant
differences between Dnase1, MMP2 or MMP9 mRNA levels in
mice from Group 1 and Group 2. In Group 3 mice, however,
Dnase1 mRNA levels were severely down-regulated compared
with mice in Group 1 (p=0.0001) and Group 2 (p=0.024).
MMP2 mRNA levels were higher in Group 3 compared with
Group 1 (p=0.009) and Group 2 (p=0.043) mice, while there
were no statistically significant differences in MMP9 mRNA levels
between the groups (Figure 2A). In Group 3 mice, proteinuria was
significantly more pronounced than in the former 2 groups of BW
mice (p,0,001, Figure 2A). The variations in Dnase1, MMP2,
and MMP9 mRNA levels were reflected in a similar variation in
enzyme activities, as demonstrated by relevant zymography
analyses (exemplified in Figure 2B, see also [29]). For more
extended analyses of mRNA levels and their correlation with
enzyme activities, see Table S1 (for mRNA levels) and Figure S1
(for zymographic Dnase1 enzyme activities in individual mice).
These results indicate that low Dnase1 activity, high MMP2
activity, and severe proteinuria are interdependent parameters
involved in development of end-stage kidney disease. Since mRNA
levels are given as exact figures, and correlate with zymography
results (Table S1 and Figure S1), which, however, are not given as
exact measures, data in the next sections are given as fold change
in Dnase1 and MMP mRNA levels.
Although not statistically significant, mean anti-dsDNA anti-
body titers were lower in Group 3, compared with Group 2 mice
(Figure 2C). In sex and age matched BALB/c mice, Dnase1,
MMP2 and MMP9 mRNA levels and enzyme activities were
present at normal and stable values throughout the observation
time (See Figure S1 for Dnase1 zymography using proteins
extracted from BALB/c kidneys). This has also been demonstrated
in a series of descriptive observations [14,15,29]. All these mice
were negative for anti-dsDNA antibodies (data not shown).
Loss of Renal Dnase1 mRNA Correlates with Increased
Renal MMP2 mRNA Levels
Dnase1 mRNA levels varied considerably in mice analyzed at
various time points over the entire observation period (Figure 3A).
Similarly, both MMP2 and MMP9 mRNA levels showed a
substantial variability with some peaks generally in mice of older
age (Figure 3B and 3C, for MMP2 and MMP9 mRNA,
respectively). Since nephritis does not appear at the same age in
individual BW mice, instead of relating data to age, levels of
Dnase1, MMP2 and MMP9 mRNA were combined for each
mouse, and this set of data was sorted by descending Dnase1
mRNA levels. As is clearly demonstrated in Figure 3D, very low
levels of Dnase1 correlated inversely with high levels of MMP2
(Table 1, correlation coefficient=20,299, p=0.016). This was
also demonstrated by a similar inverse correlation of Dnase1 and
MMP2 enzyme activities (Figure 2B and Table S1 and Figure S1,
which demonstrates that mRNA levels largely reflected enzyme
activities). This indicates that there may be a causal relationship
between loss of Dnase1 and up-regulation of MMP2 (see below).
There was no significant correlation between Dnase1 and MMP9
mRNA levels (Figure 3D, Table 1).
Proteinuria Is Not Related to Serum Anti-dsDNA Antibody
Titers, but Correlates with EDS in the GBM, and Inversely
with Renal Dnase1 mRNA Levels
In order to examine the impact of anti-dsDNA antibodies on
development of proteinuria, we analyzed if the presence of anti-
dsDNA antibodies correlated with proteinuria. These parameters
correlated with each other (p,0,001, Table 1), while titers of the
antibodies were not associated with degree of proteinuria as high
antibody titers appeared in individual mice with low degree of
proteinuria and vice versa (Figure 4A).
Next, data on proteinuria and deposition of EDS in either
the mesangial matrix only (weighted 1 in Figure 4B) or also in
the GBM (weighted 2 to make a visual distinction from deposits
in the mesangial matrix in the figure) were combined for each
mouse, and the paired data were sorted by ascending values of
proteinuria. Figure 4B shows that severe proteinuria ($20 g/L)
was, except for one mouse, exclusively observed in mice with
EDS in GBM, while intermediate or low levels of proteinuria
was observed in 4 out of the 17 mice with mesangial matrix
deposits only, which is a significantly higher number than for
mice without any EDS deposition in glomeruli (0 out of 27
mice, see Table 1 for statistics). The data also demonstrate that
deposition of chromatin fragment-IgG complexes in the
mesangial matrix may not necessarily result in clinical
nephritis. EDS deposits in the mesangial matrix may, therefore,
be compatible with a silent organ m a n i f e s t a t i o ni ni n d i v i d u a l
mice.
To further investigate the hypothesis that chromatin fragment
deposition, especially in the GBM, depends on loss of renal
Dnase1, we assessed whether severe proteinuria indeed correlated
inversely with Dnase1 mRNA levels and Dnase1 activity the same
way as severe proteinuria correlated with EDS in GBM. When
proteinuria and Dnase1 mRNA levels were combined in
individual mice, and the two parameters sorted by ascending
proteinuria, it became evident that severe proteinuria correlated
with critically down-regulated Dnase1 (Figure 4C, p,0.001,
Table 1). Thus, in mice selected on the basis of proteinuria
$20 g/L, renal Dnase1 mRNA was nearly absent in all but one
mouse (Figure 4C), and deposits of chromatin-IgG complexes
(observed as EDS) in GBM were observed only in these mice
except for one with proteinuria of 3 g/L (Figure 4B).
Presence of Anti-dsDNA Antibodies and Low Renal
Dnase1 mRNA Level and Corresponding Enzyme Activity
Correlate with the Deposition of EDS in the Mesangial
Matrix and in the GBM, Respectively
According to the data presented in Figure 4, which demonstrate
that severe proteinuria is inversely correlated with Dnase1 mRNA
levels and enzyme activities, and positively with EDS in GBM, it
was important to analyse whether low Dnase1 mRNA levels also
correlated with EDS deposition in the mesangial matrix, or only in
GBM. Data on Dnase1 mRNA levels and EDS in mesangial
matrix (weighted 1 in Figure 5A and B), or in GBM (weighted 2)
where combined and sorted by descending Dnase1 mRNA levels.
The result of this analysis is presented in Figure 5A, and
demonstrates a clear correlation between low Dnase1 mRNA
levels and the presence of EDS in GBM. Loss of Dnase1 mRNA is
also reflected by a corresponding loss of enzyme activity (see
Figure 2B and Figure S1 for representative examples). The
association of low Dnase1 mRNA levels and presence of EDS in
GBM was statistically highly significant (correlation coeffi-
cient=20,565, p,0,001, Table 1). EDS in the mesangial matrix
was not associated with Dnase1 mRNA levels (Figure 5A,
Dnase1 in Lupus Nephritis
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generated by a mechanism independent from renal Dnase1
activity.
The presence of EDS solely in the mesangial matrix was
significantly associated with the presence of anti-dsDNA antibod-
ies (Figure 5B, correlation coefficient=0,899, p,0,001, Table 1).
Figure 2. Levels of Dnase1, MMP2 and MMP9 mRNA and enzyme activities, and mean anti-dsDNA antibody titers in Group 1–Group
3 mice. There were no significant differences with respect to Dnase1, MMP2 or MMP9 mRNA levels and degree of proteinuria between Group 1 and
Group 2 mice (A). In Group 3 mice, Dnase1 mRNA levels were severely and significantly down-regulated, while MMP2 mRNA levels and proteinuria
were significantly higher than in the former 2 groups of BW mice (A). The variations in mRNA levels were reflected in a similar variation in enzyme
activities, as demonstrated in individual mice by relevant zymography analyses (exemplified in B, see also [29]). The results in A and B indicate that
low Dnase1, high MMP2 and severe proteinuria may be interdependent parameters. Mean anti-dsDNA antibody titers were lower in Group 3 mice,
compared with mice in Group 2, although the difference was not statistically significant (C). Arrows in A and B point at reduced Dnase1 mRNA levels.
Results are given as mean (6SD) and an unpaired t test was performed to determine differences between each group for each parameter. A one-way
ANOVA was performed to compare all groups for each parameter. n.s.: not significant.
doi:10.1371/journal.pone.0008474.g002
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8474Figure 3. Dnase1, MMP2 and MMP9 mRNA levels and their correlations in mice of different age. Dnase1 mRNA levels fluctuated over the
entire observation time (A). Similarly, both MMP2 and MMP9 showed a considerable variability with some peaks in mice of higher age (B and C, for
MMP2 and MMP9, respectively). To analyse if levels of Dnase1, MMP2 and MMP9 mRNA correlated with each other, the data were combined for each
mouse, and this set of data was sorted by descending Dnase1 mRNA levels. As demonstrated in panel D, very low levels of Dnase1 were inversely
correlated with high levels of MMP2 (correlation coefficient 20,299, p=0,016). This indicates that there is a link between loss of Dnase1 and up-
regulation of MMP2. Chromatin fragments that are not appropriately fragmented and cleared may be the common denominator (see text for details).
doi:10.1371/journal.pone.0008474.g003
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and in the GBM have different origins; EDS in the mesangial
matrix may depend on the presence of antibodies to dsDNA, while
deposition of EDS in GBM may be a consequence of reduced
renal Dnase1 activity. On the other hand, production of antibodies
to dsDNA did not correlate with the levels of renal Dnase1 mRNA
and enzyme activities (Figure 5C, p=0,124, Table 1).
Overall Statistical Analyses
Table 1 shows a square matrix where the upper diagonal part
demonstrates correlation coefficients, and the lower diagonal part
the corresponding p-values of the data generated in this study. In
Figure 6, the result of a principal component analysis (PCA) biplot
drawn with the R biplot function is demonstrated. The PCA biplot
is aimed to optimally display variances and not correlations. The
angles between the various biplot axes are good indicators of the
correlations among the variables (shown as arrows). The position
of the samples of individual mice (shown as plus signs) relative to
the arrows provides good indications as to which variable(s) have
had the largest effect. As is evident in data presented in Figure 6,
the mice confine perfectly into three groups, one pre-nephritic,
one with mild mesangial nephritis, and one with end-stage
membrano-proliferative nephritis (see Figure S2 to identify the
grouped mice in Figure 6 by labels). This result confirms that the
parameters used to group BW mice as in Figure 1 and Figure 2 are
biologically relevant.
Discussion
The basic hypothesis motivating the present study was that
clinical lupus nephritis is a distinct organ disease with an aetiology
linked to an acquired loss of renal Dnase1 enzyme activity.
Acquired deficiency of renal Dnase1 activity is assumed to
promote a progressive exposure of secondary necrotic chromatin
in GBM, and a consequent development of severe nephritis
[30,31]. This may, however, be restricted to individuals with anti-
chromatin antibodies. In the absence of anti-chromatin antibodies,
exposed chromatin may be more or less harmless. Similarly,
antibodies in the absence of exposed chromatin may render them
apathogenic. This latter statement relates to their pathogenic
[30,31], but not to their diagnostic impact [32]. The lupus
nephritis phenotype is, therefore, characterized by glomerular
binding of complexes of chromatin fragments and anti-chromatin
antibodies.
Data so far demonstrate that accumulation of chromatin
fragment-IgG complexes correlates with a progressive loss of
renal Dnase1 enzyme activity [14] and with increased renal
MMP2 and, to a lesser extent, MMP9 activities [28,29]. MMPs
may disrupt and disintegrate mesangial matrix and GBM [26,27].
These two events explain why large chromatin fragments
generated within the kidneys finally get access to GBM. Therefore,
loss of Dnase1 and increased MMP activities are identified as
factors that may contribute to transformation of mild mesangial
into severe membrano-proliferative lupus nephritis.
In this study we analyzed if loss of renal Dnase1 correlated with
increased MMP activity in the kidneys, and with exposure of large
chromatin fragments at loci typical for lupus nephritis–namely in
the mesangial matrix and in the GBM. A series of baseline data
were collected in groups (n=3) of mice at consecutive intervals.
These were combined to analyse if regulation of Dnase1, MMP2
and MMP9 mRNA levels and enzyme activities (analyzed by
relevant zymography assays) correlated with the production of
antibodies to dsDNA, and with the successive deposition of EDS in
the mesangial matrix and in GBM in individual mice. In the end,
these factors were correlated with progressive proteinuria and end-
stage organ disease.
For each parameter, it was difficult to determine correlation
between e.g. Dnase1, MMP2 or MMP9 mRNA levels with age in
individual mice since nephritis developed at different time points
in different mice. However, by combining data obtained in each
mouse, and by sorting them by parameters one by one at the time
in an ascending or descending way, clear correlations became
apparent. For example, a combination of the highest values for
MMP2 combined with chromatin fragments accumulated in
GBM were only observed in mice with the lowest renal Dnase1
mRNA levels. This indicates that these kidneys have entered the
state of end-organ disease when Dnase1 mRNA and enzyme
activity were at the lowest levels. Similarly, sorting data by
increasing proteinuria, it became evident that mice with severe
proteinuria had the lowest levels of renal Dnase1. These
observations fit with the hypothesis that reduced Dnase1 mRNA
level and enzyme activity result in reduced fragmentation of
Table 1. Statistical analyses of the parameters analyzed: Correlations and significances.
1
Age Dnase1 MMP2 MMP9 EDS
2 MM
3 EDS GBM
4 Anti-DNA abs
5 Proteinuria
Age - 20.220 0.052 20.166 0.783 0.519 0.754 0.643
Dnase1 0.057 - 20.299 0.018 0.051 20.565 20.124 20.693
MMP2 0.500 0.016 - 0.719 20.029 0.345 0.138 0.227
MMP9 0.271 0.911 ,0.001 - 20.130 0.028 20.149 20.078
EDS MM
6 ,0.001 0.740 0.850 0.399 - 0.477 0.899 0.450
EDS GBM ,0.001 ,0.001 0.010 0.835 ,0.001 - 0.456 0.836
Anti-DNA abs ,0.001 0.124 0.221 0.333 ,0.001 0.001 - 0.540
Proteinuria ,0.001 ,0.001 0.062 0.589 0.002 ,0.001 ,0.001 -
1Upper diagonal part contains correlation coefficient estimates, lower diagonal part (in bold) contains corresponding p-values.
2EDS: electron dence structures.
3MM: mesangial matrix.
4GBM: glomerular basement membranes.
5abs: antibodies.
6Correlation and corresponding p-values for EDS in mesangial matrix are calculated from mice with no glomerular EDS, or EDS in the mesangial matrix only. In these
calculations, we excluded mice with EDS in GBM, since all these have mesangial matrix deposits, while the biological consequences of EDS in GBM overrule those of
EDS in the mesangial matrix (see text).
doi:10.1371/journal.pone.0008474.t001
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8474Figure 4. Severe proteinuria correlates with EDS deposits in GBM, and inversely with renal Dnase1 mRNA levels. In mice sorted for
age, there was no association between degree of proteinuria and levels of anti-dsDNA antibody titers (A). To analyse if location of EDS deposits had
impact on proteinuria, data on proteinuria and deposition of EDS in the mesangial matrix (weighted 1 in B) or in the GBM (weighted 2 to make a
visual distinction from deposits in the mesangial matrix) were combined for each mouse, and sorted by ascending values of proteinuria. Severe
proteinuria ($20 g/L) was, except for one mouse with intermediate proteinuria (#3 g/L), exclusively observed in mice with EDS in GBM (B), while
intermediate or mild proteinuria was observed in only 4 out of 17 mice with mesangial matrix deposits (B). In panel C, degree of proteinuria and renal
Dnase1 mRNA levels were paired and sorted by ascending proteinuria. Severe proteinuria ($20 g/L) correlated with a substantial loss of Dnase1
mRNA (and enzyme activity, see Figure 2). Thus, in mice selected for proteinuria $20 g/L, renal Dnase1 mRNA was nearby lost in all but one mouse
(C), and deposits of chromatin-IgG complexes (observed as EDS) in GBM were observed only in these mice. For statistics, see Table 1.
doi:10.1371/journal.pone.0008474.g004
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8474Figure 5. Anti-dsDNA antibodies and renal Dnase1 levels, and their correlation with EDS in mesangial matrix and GBM,
respectively. Data on Dnase1 mRNA levels and EDS in the mesangial matrix (weighted 1 in Figure 5A and B), or in GBM (weighted 2) where
combined for each mouse and sorted by descending Dnase1 mRNA levels. The result of this analysis demonstrates a clear negative correlation
between Dnase1 mRNA levels and presence of EDS in GBM. This association was statistically highly significant (A, see Table 1 for statistical analyses).
The inverse correlation of EDS in the mesangial matrix with Dnase1 mRNA levels was weaker, and did not reach statistical significance (A, Table 1).
The presence of EDS solely in the mesangial matrix was significantly associated with production of anti-dsDNA antibodies (B, Table 1). This
demonstrates that deposition of EDS in the mesangial matrix and in the GBM may originate from different molecular processes; EDS in mesangial
matrix depend on presence of antibodies to dsDNA, while EDS in GBM depend on reduced renal Dnase1 activity. Production and titers of antibodies
to dsDNA was not significantly associated with levels of renal. Dnase1 mRNA and enzyme activities (C, Table 1).
doi:10.1371/journal.pone.0008474.g005
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instead of being cleared, retained in tissue, and exposed to
infiltrating dendritic cells and macrophages. Upon interaction of
chromatin with TLRs in these cells, co-stimulatory molecules
(CD80/CD86) are up-regulated, while peptides from the same
chromatin fragments may get processed, and presented by MHC
class II molecules. This may, although not proven by data, be
sufficient to activate chromatin-specific T cells with potential to
transform chromatin-specific B cells into antibody-secreting
plasma cells [21,30,33].
On the other hand, chromatin fragments that are not
appropriately fragmented and cleared may be the factor that
determines if induced anti-chromatin antibodies gain pathogenic
potential. This can only happen if chromatin is exposed and
thereby made available for such antibodies. One factor that can
exaggerate this situation is increased secretion of MMPs, since
chromatin fragments have the potential to up-regulate MMP
production and secretion through activation of the TLR9 signaling
pathway [22,23,34,35]. This does not rule out that other
mechanisms may contribute to increased production of MMPs
Figure 6. A principal component analysis (PCA) of parameters included in this study. This PCA biplot aims to optimally display variances
and not correlations. The angles between the various biplot axes serve as good indicators of the correlations among the variables (shown as arrows).
Similarly, the position of the samples of individual mice (shown as plus signs) relative to the arrows, provide good indications as to which variable(s)
have had the largest effect. The result of the biplot demonstrates that groups emerging from this analysis perfectly correlated with the groups of BW
mice as defined in Figure 1 and Figure 2, defined as pre-nephritic BW mice (Group 1), BW mice with deposits of EDS in the mesangial matrix (Group 2)
or with deposits in the GBM (Group 3). The circle identifies the mouse with the lowest renal Dnase1 mRNA level and enzyme activity, and the highest
MMP2 and MMP9 mRNA levels and enzyme activities and with proteinuria $20 g/L.
doi:10.1371/journal.pone.0008474.g006
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MMP activity within glomeruli may, therefore, be a result of an
inflammatory process maintained by retained necrotic cellular
debris linked to loss of apoptosis- and necrosis-related Dnase1
enzyme activity [38,39]. Continuously increased matrix degrada-
tion by the MMPs may disrupt GBM integrity and thereby
promote deposition of immune complexes in these structures, as
discussed by Tveita et al. [29]. This process is reflected by the data
presented in this study, where loss of Dnase1 correlated with
increased MMP2 mRNA levels and enzyme activities in affected
kidneys; with increased exposure of chromatin fragments in
complex with IgG within GBM; and with severe proteinuria
($20 g/L). These results create the basis for similar studies in
human lupus nephritis. Preliminary results from analyses of kidney
biopsies from patients with human lupus nephritis demonstrate a
similar relationship between severe nephritis and loss of the
Dnase1 enzyme (studies in progress).
Since deposition of EDS in the mesangial matrix preceded
reduced renal Dnase1 levels, this less harmful process has another
origin. In the data sets presented here, it is evident that deposition
of EDS in the mesangial matrix correlated significantly with
appearance of anti-dsDNA antibodies in sera. An explanation for
this linkage may be that circulating nucleosomes [40–42] bind
nucleosome-reactive antibodies, and re-circulate as immune
complexes. These may be bound to glomerular mesangial cells
through Fc regions of IgG in the complexes, since these cells
express Fcc-receptors [43]. If the amount of immune complexes
exceeds the clearance capacity of mesangial cells, this could result
in release of immune complexes into the mesangial matrix
surrounding these cells.
The consequent interpretation of the data presented here is that
lupus nephritis is a principally two-stepped organ disease where
each step has its distinct aetiology. The early phase of lupus
nephritis correlates with deposition of complexes of chromatin
fragments and IgG in the mesangial matrix. This process is
associated with the production of anti-DNA (anti-chromatin)
antibodies, and is characterized by mild or clinically silent
nephritis. This process is consistent with an observed drop in
serum concentration of DNA (nucleosomes) at the time when anti-
dsDNA antibodies appeared in circulation, as determined by real
time PCR applied to serial serum samples from BW mice or to
sera from human SLE patients. This real time PCR was
performed with Alu- (human) or B1- (mouse) specific primers (M
Hellvik Jørgensen et al., manuscript in preparation).
At a certain time point in the life of BW mice, the renal Dnase1
mRNA and enzyme activity is inevitably lost. Importantly,
reduced renal Dnase1 activity manifests itself at the same time
fragmentation of chromatin in kidneys is reduced. The reason for
the loss of renal Dnase1 is uncertain, and may involve different
processes. Alteration of the Dnase1 promoter (promoter methyl-
ation, [44]), and the effect of regulatory RNA (like microRNA,
[45]) are likely and testable processes. Of particular interest,
however, is the fact that the hsp90-related protein Trap1 is
encoded the opposite direction of Dnase1, and uses down-stream
sequence elements of the Dnase1 gene (see http://genome.ucsc.
edu). This means that the two genes may not be transcribed at the
same time, and therefore, they may mutually exclude each other.
Trap1 is up-regulated during stress and has the function of a
survival protein [46,47]. Thus, Dnase1, as a death-associated
protein, and Trap1 have antagonistic effects, and possibly also
antagonistic expression profiles. These aspects are currently under
investigation in our laboratory.
To understand how the Dnase1 gene is down-regulated in the
kidney may bring us a significant step towards the understanding
of the molecular and genetical events that in the end result in
progressive lupus nephritis. This insight is decisive to create a basis
for development of new causal therapy modalities.
Materials and Methods
Ethics Statement
The National Animal Research Authority (NARA) approved
the study. Treatment and care of animals were conducted in
accordance with guidelines of the Norwegian Ethical and Welfare
Board for Animal Research.
Murine Tissue Samples
Renal tissue was collected from female (NZBxNZW)F1 (BW)
and female age-matched BALB/c mice (Jackson Laboratory, Bar
Harbor, Maine, USA) sacrificed approximately every second week
(n=3) from the age of 4 weeks until development of end-stage
disease in the BW mice, clinically defined when severe proteinuria
developed ($20 g/L). Tissue was either snapfrozen for protein
extraction, preserved according to Tokuyasu for immune electron
microscopy [48], or preserved in RNAlater (Ambion Inc., Texas,
USA) for mRNA analyses. Serum and urine samples were
collected at 2–3 week intervalls and stored at 280uC.
Determination of Proteinuria
Proteinuria was determined by urine stix (Bayer Diagnostics,
Bridgend, United Kingdom): 0–1+ (#0.3 g/L, regarded as
physiological proteinuria); 2+,( #1 g/L); 3+,( #3 g/L); and 4+,
($20 g/L).
Anti-dsDNA Antibody ELISA
Serum anti-dsDNA antibodies were detected and controlled by
ELISA as described [32,49], using microtiter plates (Nunc
MaxiSorp; Nunc, Copenhagen, Denmark) coated with calf thymus
dsDNA (10 mg/ml in PBS, Sigma-Aldrich, Saint Louis, USA).
Immune Electron Microscopy (IEM)
For immune electron microscopy, kidney samples were fixed in
8% formaldehyde in PBS, further processed in sucrose and glycine
before mounted and immersed in liquid nitrogen as described
[48]. Ultrathin cryosections were processed as described [12] to
correlate the morphological changes with the presence of
autoantibodies bound in the glomeruli in vivo. The grids were
contrasted with uranyl acetate and examined at 620–640 K
magnification using a JEM-1010 transmission electron microscope
(Jeol, Tokyo, Japan).
Purification of Renal RNA and cDNA Synthesis
Total RNA was isolated from RNAlater-preserved kidneys
using EZ-1 RNA tissue mini kit (Qiagen, Nordic, Norway). The
kidneys were taken from all mice included in this study. These are
listed in Table S1. The concentration of extracted RNA was
determined by spectrophotometry using NanoDrop (NanoDrop
technologies, Wilmington, USA), and quality was assessed using
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, USA).
Samples were reverse-transcribed with random primers using
High Capacity cDNA Reverse Transcription kit (Applied
Biosystems, Foster City, USA).
Real-Time PCR Analysis
For real time PCR we used TaqManH Gene Expression Assays
(Applied Biosystems, CA, USA): Dnase1 Mm01342389_g1;
MMP2 Mm00439508_m1; MMP9 Mm00442991_m1; endoge-
Dnase1 in Lupus Nephritis
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8474nous control–Mouse ACTB (actin, beta) 4352933E and TATA
binding protein Mm00446973_m1. The assays were performed on
ABI Prism 7900HT Sequence Detection System (Applied
Biosystems). Expression levels were calculated using the DDCT
method. Data are given as fold change compared to transcription
in 4 weeks old mice.
Purification of Renal Proteins
ProteinswerepurifiedfromkidneysaccordingtoWoessner[50] as
described by Tveita et al. [28]. Briefly, snapfrozen cortical tissue was
homogenized in Tris buffer (0.5 mol/l Tris-HCl, pH 7.5,
150 mmol/l NaCl). The mixture was centrifuged and the superna-
tants were collected. The pellets were resuspended in heat extraction
buffer(50 mMTrispH 7.5,0.1 MCaCl2,0.15 MNaCl),incubated
for 4 min at 60uC, and centrifuged. The supernatants were
combined, and protein content was determined using BCA assay
kit (Pierce Biochemicals, IL, USA). These preparations were used for
Dnase1, MMP2 and MMP9 gel zymography.
Dnase1 and MMP Gel Zymography
DNA degrading activity by Dnase1 was determined after
separation of renal proteins in a 10% SDS-polyacrylamide gel
containing 100 mg/ml heat-denatured salmon sperm DNA (Invitro-
gen Corp., Carlsbad, CA) as described [51]. MMP2 and MMP9
zymography was performed as described by Tveita et al. [29], as
follows. After protein purification, proteins were separated on 7.5%
SDS-PAGE gels containing gelatin (1.0 mg/ml). Following electro-
phoresis, gels were washed for 1 h in 2% Triton X-100 in 50 mM
Tris-HCl, pH 7.4, followed by incubation at 37uC for 20 h in
activation buffer (50 mM Tris-HCl, pH 7.4, 5 mM CaCl2). Gels
were stained with Coomassie Blue. Clear zones against the
background demonstrated presence of protease activity, and
MMP2 and MMP9 were detected by MW according to position
of recombinant enzymes in the gel. An actin-specific Western blot
was performed to ensure equal loading of the different renal protein
preparations using a rabbit IgG anti-actin antibody (Sigma-Aldrich).
Statistics
Data are presented as mean with standard deviation (SD). An
unpaired t-test was performed to test differences between each
group and a one-way ANOVA was performed to compare all
groups for each parameter; p,0.05 was considered significant.
The rcor.test function from the R language ltm package was used
to generate data in Table 1. All observations were included and
Spearman was used for significance testing. A principal compo-
nent analysis (PCA) was performed on the same set of data and a
biplot drawn with the R biplot function (Figure 6).
Supporting Information
Table S1 Summary of data on mRNA levels of Dnase1, MMP2,
and MMP9, anti-dsDNA antibody titers, deposits of immune
complexes in the mesangial matrix and GBM, and proteinuria
linked to each individual (NZBxNZW)F1 mice which are
identified by labels.
Found at: doi:10.1371/journal.pone.0008474.s001 (0.03 MB
XLS)
Figure S1 Dnase1 gel zymography is given for each
(NZBxNZW)F1 and BALB/c mouse included in the study. This
figure, combined with the Dnase1 mRNA levels presented in
Table S1 demonstrate that levels of Dnase1 mRNA correspond
with levels of Dnase1 enzyme activity.
Found at: doi:10.1371/journal.pone.0008474.s002 (1.99 MB TIF)
Figure S2 This figure is identical to Figure 6 in the manuscript,
with the additional information that each mouse can be identified
by the same labels as in Table S1. The result of the biplot
demonstrates that groups emerging from this analysis perfectly
correlated with the groups of BW mice as given in Figure 1 and
Figure 2, defined as pre-nephritic BW mice (Group 1), BW mice
with deposits of EDS in the mesangial matrix (Group 2) or with
deposits in the GBM (Group 3).
Found at: doi:10.1371/journal.pone.0008474.s003 (0.11 MB TIF)
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